A Heterodimer of a VHH (Variable Domains of Camelid Heavy Chain-only) Antibody That Inhibits Anthrax Toxin Cell Binding Linked to a VHH Antibody That Blocks Oligomer Formation Is Highly Protective in an Anthrax Spore Challenge Model-Reference-Cited by-同舟云学术

A Heterodimer of a VHH (Variable Domains of Camelid Heavy Chain-only) Antibody That Inhibits Anthrax Toxin Cell Binding Linked to a VHH Antibody That Blocks Oligomer Formation Is Highly Protective in an Anthrax Spore Challenge Model

Published:2015-03 Issue:10 Volume:290 Page:6584-6595
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Moayeri Mahtab,Leysath Clinton E.,Tremblay Jacqueline M.,Vrentas Catherine,Crown Devorah,Leppla Stephen H.,Shoemaker Charles B.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference43 articles.

1. Anthrax lethal and edema toxins in anthrax pathogenesis;Liu;Trends Microbiol,2014

2. Cellular and systemic effects of anthrax lethal toxin and edema toxin;Moayeri;Mol. Aspects Med,2009

3. Monoclonal antibody therapies against anthrax;Chen;Toxins,2011

4. Anthrax vaccines: present status and future prospects;Kaur;Expert Rev. Vaccines,2013

5. Nanobodies: natural single-domain antibodies;Muyldermans;Annu. Rev. Biochem,2013

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single domain antibodies from camelids in the treatment of microbial infections;Frontiers in Immunology;2024-05-17

2. Food-Borne Biotoxin Neutralization in Vivo by Nanobodies: Current Status and Prospects;Journal of Agricultural and Food Chemistry;2024-05-06

3. Single-Domain Antibody Multimers for Detection of Botulinum Neurotoxin Serotypes C, D, and Their Mosaics in Endopep-MS;Toxins;2023-09-17

4. Nanobodies: The potential application in bacterial treatment and diagnosis;Biochemical Pharmacology;2023-08

5. Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context;BioDrugs;2023-02-02